Previous close | 23.53 |
Open | 23.90 |
Bid | 22.14 x 100 |
Ask | 23.55 x 100 |
Day's range | 22.50 - 23.90 |
52-week range | 7.93 - 33.00 |
Volume | |
Avg. volume | 87,353 |
Market cap | 1.216B |
Beta (5Y monthly) | -3.12 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.82 |
Earnings date | 06 May 2024 - 10 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 33.60 |
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis of HAE attacksStrengthened executive committee with hiring of David Nassif, J.D., Chief Financial Officer, and Stefan Abele, Ph.D., as Chief Technical Operations OfficerUK Innovation Passport awarded to deucrictibant for both the on-demand and prophylactic treatment of HAE atta
ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of David Nassif, J.D., as Chief Financial Officer, effective April 15, 2024. In this role, he will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and o